Resources


March 18, 2020

iBio Announces Development of Proprietary COVID-19 Vaccine Candidates

Several Provisional Patents Filed with USPTO NEW YORK, March 18, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today announced its progress ...

Continue Reading

March 13, 2020

iBio Announces Leadership Succession, Appoints Thomas F. Isett Co-Chairman & CEO

NEW YORK, March 12, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced the appointment of accomplished life sciences executive, Thomas F. Isett, as its Co-Chairman and Chief Executive Officer. Mr. Isett, a ...

Continue Reading

February 4, 2020

iBio and CC-Pharming Initiate Joint Development of Coronavirus Vaccine

NEW YORK, Feb. 03, 2020 (GLOBE NEWSWIRE) -- In response to investor and media inquiries regarding their initiatives to address the coronavirus outbreak, iBio, Inc. (NYSE AMERICAN:IBIO) and Beijing CC-Pharming Ltd., today announced their collaboration to ...

Continue Reading

December 24, 2019

iBio Announces Collaboration with EdgePoint AI for Next Gen Quality in Biologics Manufacturing

NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc. (OTCQB:MATN), to deploy EdgePoint’s proprietary artificial ...

Continue Reading

December 16, 2019

iBio Reports Progress on its Bio-Better Rituximab Collaboration with CC-Pharming

Presentation Demonstrates Advantages of iBio’s Recently Launched FastGlycaneering Development Service™ -

Continue Reading
1 2 3 4